Biosite(R) Diagnostics and American Biogenetic Sciences Sign a Research and License Agreement for TpP

TpP Test is Cleared for Marketing to Detect Levels of

a Blood Protein Whose Levels Rise Before a Clot Forms



Apr 03, 2001, 01:00 ET from American Biogenetic Sciences, Inc.

    COPIAGUE, N.Y., April 3 /PRNewswire/ --
 American Biogenetic Sciences, Inc. (ABS) (Nasdaq: MABA) announced today that
 it has entered into a research and non-exclusive license agreement with
 Biosite Diagnostics, Incorporated (Nasdaq: BSTE) to validate the use of ABS'
 Thrombus Precursor Protein (TpP(TM)) diagnostic marker and antibodies for
 potential use with Biosite's rapid, quantitative Triage(R) Meter testing
 platform.
     Biosite will conduct an evaluation of the TpP assay as part of its
 on-going discovery program aimed at the identification of diagnostic markers
 for cardiovascular and cerebrovascular diseases. Should Biosite commercialize
 a product containing ABS' patented monoclonal antibodies, Biosite will
 purchase the antibodies from ABS and pay milestone fees and royalties. In
 assessing diagnostic utilities of potential markers, Biosite will use blood
 samples from clinical collaborators such as the Thrombolysis In Myocardial
 Infarction (TIMI) study group of Brigham and Woman's Hospital, an
 investigative team that has been at the forefront of clinical research of
 acute coronary syndromes for the past two decades.
     "Biosite's evaluation of TpP could further establish the utility of this
 sensitive antibody-based assay and lead to its use on Biosite's point-of-care
 testing platform," said Josef C. Schoell, ABS' president.
     "A recent publication(1) using the TpP ELISA supports the utility of this
 protein as a marker for the diagnosis and management of chest pain patients
 experiencing an MI," said David Carville, Ph.D., Cardiovascular Consultant to
 ABS. "After the research is completed, TpP may emerge as a useful adjunct to
 future generations of Biosite products."
     The TpP assay is based on ABS' highly specific patented MH-1 monoclonal
 antibody, a product of its patented Antigen-Free antibody generation
 technology.  The TpP diagnostic is approved for use in aiding in the risk
 assessment of thrombosis and the monitoring of anticoagulant (heparin)
 therapy.
     Biosite's rapid, quantitative Triage(R) Meter was first commercialized as
 the testing platform for the Triage Cardiac System, which provides
 measurements of cardiac markers.  The Triage Cardiac System aids in the
 diagnosis of AMI, or heart attack, by detecting and measuring three blood
 proteins (creatinine kinase [CK-MB isoenzyme], myoglobin, and troponin I) that
 are released as a result of heart muscle damage following a heart attack.
 Results from the system are available within 20 minutes.
     The American Heart Association estimates that of the 2.5 million people
 admitted to critical care with heart attack-like symptoms, only 900,000, or
 roughly 35 percent, have actually experienced an acute myocardial infarction.
 The Triage panel of rapid test for key cardiac markers is designed to help
 "rule in" or "rule out" heart attack as the cause of the symptoms.
 
     American Biogenetic Sciences, Inc., based in Copiague, N.Y., researches
 and develops diagnostic tests for cardio-pulmonary conditions and infectious
 diseases, as well as for new treatments for neurological disorders including
 epilepsy, migraine, mania, Parkinson's disease and Alzheimer's disease.
 
      Note:
      (1) Song KS, et al Clinical Usefulness of Thrombosis Precursor Protein
          (TpP) in the Diagnosis of Ischemic Heart Disease and Changes of TpP
          after LMWH Therapy.  Proceedings of the 03rd International Congress
          on Coronary Artery Disease 2000; 443-447. Moduzzi Editore SpA,
          publisher.
 
     Statements in this press release that are not strictly historical are
 "forward looking" statements within the meaning of the Private Securities
 Litigation Reform Act of 1995, and should be considered as subject to various
 risks and uncertainties that could cause actual results to differ materially
 from those anticipated, including the risk that Biosite may determine not to
 commercialize the TpP assay. For further details and a discussion of these
 risks and uncertainties, see the Company's Securities and Exchange Commission
 filings including its annual report on Form 10-K.
 
 

SOURCE American Biogenetic Sciences, Inc.
    COPIAGUE, N.Y., April 3 /PRNewswire/ --
 American Biogenetic Sciences, Inc. (ABS) (Nasdaq: MABA) announced today that
 it has entered into a research and non-exclusive license agreement with
 Biosite Diagnostics, Incorporated (Nasdaq: BSTE) to validate the use of ABS'
 Thrombus Precursor Protein (TpP(TM)) diagnostic marker and antibodies for
 potential use with Biosite's rapid, quantitative Triage(R) Meter testing
 platform.
     Biosite will conduct an evaluation of the TpP assay as part of its
 on-going discovery program aimed at the identification of diagnostic markers
 for cardiovascular and cerebrovascular diseases. Should Biosite commercialize
 a product containing ABS' patented monoclonal antibodies, Biosite will
 purchase the antibodies from ABS and pay milestone fees and royalties. In
 assessing diagnostic utilities of potential markers, Biosite will use blood
 samples from clinical collaborators such as the Thrombolysis In Myocardial
 Infarction (TIMI) study group of Brigham and Woman's Hospital, an
 investigative team that has been at the forefront of clinical research of
 acute coronary syndromes for the past two decades.
     "Biosite's evaluation of TpP could further establish the utility of this
 sensitive antibody-based assay and lead to its use on Biosite's point-of-care
 testing platform," said Josef C. Schoell, ABS' president.
     "A recent publication(1) using the TpP ELISA supports the utility of this
 protein as a marker for the diagnosis and management of chest pain patients
 experiencing an MI," said David Carville, Ph.D., Cardiovascular Consultant to
 ABS. "After the research is completed, TpP may emerge as a useful adjunct to
 future generations of Biosite products."
     The TpP assay is based on ABS' highly specific patented MH-1 monoclonal
 antibody, a product of its patented Antigen-Free antibody generation
 technology.  The TpP diagnostic is approved for use in aiding in the risk
 assessment of thrombosis and the monitoring of anticoagulant (heparin)
 therapy.
     Biosite's rapid, quantitative Triage(R) Meter was first commercialized as
 the testing platform for the Triage Cardiac System, which provides
 measurements of cardiac markers.  The Triage Cardiac System aids in the
 diagnosis of AMI, or heart attack, by detecting and measuring three blood
 proteins (creatinine kinase [CK-MB isoenzyme], myoglobin, and troponin I) that
 are released as a result of heart muscle damage following a heart attack.
 Results from the system are available within 20 minutes.
     The American Heart Association estimates that of the 2.5 million people
 admitted to critical care with heart attack-like symptoms, only 900,000, or
 roughly 35 percent, have actually experienced an acute myocardial infarction.
 The Triage panel of rapid test for key cardiac markers is designed to help
 "rule in" or "rule out" heart attack as the cause of the symptoms.
 
     American Biogenetic Sciences, Inc., based in Copiague, N.Y., researches
 and develops diagnostic tests for cardio-pulmonary conditions and infectious
 diseases, as well as for new treatments for neurological disorders including
 epilepsy, migraine, mania, Parkinson's disease and Alzheimer's disease.
 
      Note:
      (1) Song KS, et al Clinical Usefulness of Thrombosis Precursor Protein
          (TpP) in the Diagnosis of Ischemic Heart Disease and Changes of TpP
          after LMWH Therapy.  Proceedings of the 03rd International Congress
          on Coronary Artery Disease 2000; 443-447. Moduzzi Editore SpA,
          publisher.
 
     Statements in this press release that are not strictly historical are
 "forward looking" statements within the meaning of the Private Securities
 Litigation Reform Act of 1995, and should be considered as subject to various
 risks and uncertainties that could cause actual results to differ materially
 from those anticipated, including the risk that Biosite may determine not to
 commercialize the TpP assay. For further details and a discussion of these
 risks and uncertainties, see the Company's Securities and Exchange Commission
 filings including its annual report on Form 10-K.
 
 SOURCE  American Biogenetic Sciences, Inc.

RELATED LINKS

http://MABXA.com